CA3033971A1 - Ppar.gamma. agonist for treatment of bone disorders - Google Patents

Ppar.gamma. agonist for treatment of bone disorders Download PDF

Info

Publication number
CA3033971A1
CA3033971A1 CA3033971A CA3033971A CA3033971A1 CA 3033971 A1 CA3033971 A1 CA 3033971A1 CA 3033971 A CA3033971 A CA 3033971A CA 3033971 A CA3033971 A CA 3033971A CA 3033971 A1 CA3033971 A1 CA 3033971A1
Authority
CA
Canada
Prior art keywords
subject
int131
therapeutically effective
effective amount
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3033971A
Other languages
English (en)
French (fr)
Inventor
Dennis Lanfear
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Intekrin Therapeutics Inc
Original Assignee
Intekrin Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Intekrin Therapeutics Inc filed Critical Intekrin Therapeutics Inc
Publication of CA3033971A1 publication Critical patent/CA3033971A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Management, Administration, Business Operations System, And Electronic Commerce (AREA)
CA3033971A 2016-08-18 2017-08-18 Ppar.gamma. agonist for treatment of bone disorders Pending CA3033971A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662376732P 2016-08-18 2016-08-18
US62/376,732 2016-08-18
PCT/US2017/047584 WO2018035449A1 (en) 2016-08-18 2017-08-18 Pparϒ agonist for treatment of bone disorders

Publications (1)

Publication Number Publication Date
CA3033971A1 true CA3033971A1 (en) 2018-02-22

Family

ID=61197122

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3033971A Pending CA3033971A1 (en) 2016-08-18 2017-08-18 Ppar.gamma. agonist for treatment of bone disorders

Country Status (11)

Country Link
US (1) US20190167660A1 (cg-RX-API-DMAC7.html)
EP (1) EP3500269A4 (cg-RX-API-DMAC7.html)
JP (2) JP2019524889A (cg-RX-API-DMAC7.html)
KR (1) KR20190065252A (cg-RX-API-DMAC7.html)
CN (1) CN109843292A (cg-RX-API-DMAC7.html)
AU (1) AU2017313842A1 (cg-RX-API-DMAC7.html)
BR (1) BR112019003133A2 (cg-RX-API-DMAC7.html)
CA (1) CA3033971A1 (cg-RX-API-DMAC7.html)
EA (1) EA201990513A1 (cg-RX-API-DMAC7.html)
SG (2) SG10202101500WA (cg-RX-API-DMAC7.html)
WO (1) WO2018035449A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20220070057A (ko) 2015-03-09 2022-05-27 인테크린 테라퓨틱스, 아이엔씨. 비알코올성 지방간 질환 및/또는 지방이영양증의 치료 방법
SG11201909046XA (en) 2017-04-03 2019-10-30 Coherus Biosciences Inc PPARγ AGONIST FOR TREATMENT OF PROGRESSIVE SUPRANUCLEAR PALSY

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2407587A1 (en) * 2000-04-28 2001-11-08 Sankyo Company, Limited Ppar.gamma. modulators
US7223761B2 (en) * 2003-10-03 2007-05-29 Amgen Inc. Salts and polymorphs of a potent antidiabetic compound
CA2555914A1 (en) * 2004-03-08 2005-09-22 Amgen Inc. Therapeutic modulation of ppar (gamma) activity
AU2014212740B2 (en) * 2013-01-30 2015-12-24 Intekrin Therapeutics, Inc. PPARy agonists for treatment of multiple sclerosis
MY194308A (en) * 2014-10-10 2022-11-27 Prometic Pharma Smt Ltd Substituted aromatic compounds and pharmaceutical compostions for the prevention and treatment of osteoporosis

Also Published As

Publication number Publication date
EP3500269A1 (en) 2019-06-26
WO2018035449A1 (en) 2018-02-22
JP2022116294A (ja) 2022-08-09
SG11201901328VA (en) 2019-03-28
US20190167660A1 (en) 2019-06-06
JP2019524889A (ja) 2019-09-05
EA201990513A1 (ru) 2019-08-30
SG10202101500WA (en) 2021-03-30
CN109843292A (zh) 2019-06-04
EP3500269A4 (en) 2020-04-15
AU2017313842A1 (en) 2019-03-07
KR20190065252A (ko) 2019-06-11
BR112019003133A2 (pt) 2019-05-21

Similar Documents

Publication Publication Date Title
US11324735B2 (en) Method of treatment with tradipitant
US12458626B2 (en) Methods for treating heterotopic ossification
US9867816B2 (en) PPARγ agonists for treatment of multiple sclerosis
JP2022116294A (ja) 骨疾患の治療のためのＰＰＡＲγアゴニスト
Ebeling et al. Teriparatide (rhPTH 1–34) for the treatment of osteoporosis
JP2005526022A5 (ja) 関節リウマチの処置
EP3570841A1 (en) PPARy AGONIST FOR THE TREATMENT OF HUNTINGTON'S DISEASE
JP6839076B2 (ja) 変形性関節症の治療のためのネリドロン酸またはその塩の使用
Winkelmann Evidence for better response to somatostatin analogue treatment in acromegalic patients treated with metformin
RU2810253C2 (ru) Способ лечения с применением традипитанта
CN101448496A (zh) 治疗遗传性血色病的方法
Cusano et al. Newer Adult Bone Drugs
EA040332B1 (ru) РАППγ АГОНИСТЫ ДЛЯ ЛЕЧЕНИЯ РАССЕЯННОГО СКЛЕРОЗА

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20220817

EEER Examination request

Effective date: 20220817

EEER Examination request

Effective date: 20220817

EEER Examination request

Effective date: 20220817